Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 3802876 in Healthy Men
NCT06081530Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of bi 3802876 (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrences of any drug-related Adverse Events at Day 117. Started Oct 2023; status: completed.
02
Drugs
bi 3802876
Beyond the preview
Go deeper on NCT06081530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081530.